Q SYNTHESIS LLC
  • Quality Improvement
  • Systems Thinking
  • Implementation Science
  • Publications
  • About
  • Contact
  • Updates

The Science of HER2-low Breast Cancer and Implications for the Pathology Team

2/23/2022

 
This virtual tumor board from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.
Claim CME/CMLE credit at: ​https://store.ascp.org/productlisting/productdetail?productId=143142647

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
​

Comments are closed.

    Author

    @DrJosephKim
    Joseph Kim, MD, MPH, MBA, FACEHP is the Founder and President of Q Synthesis LLC.

    ​View Dr. Kim's bio on LinkedIn. 

    ​


    Sign up to receive updates:
Q Synthesis LLC
Home

About

Contact
​

​Publications
Picture
​Quality Improvement 
​
Systems Thinking 

​Implementation Science 

​Updates
www.qsynthesis.com
  • Quality Improvement
  • Systems Thinking
  • Implementation Science
  • Publications
  • About
  • Contact
  • Updates